LABFF (Laboratorios Farmaceuticos Rovi) Ending Cash Position: $112.6 Mil (As of Mar. 2026)


LABFF Laboratorios Farmaceuticos Rovi SA LABFF
93 GF Score
Price $90.61
GF Value $82.42
! 1 Warning Sign
View Full Analysis

What is Laboratorios Farmaceuticos Rovi Ending Cash Position?

Laboratorios Farmaceuticos Rovi LABFF 93 Ending Cash Position is $112.6 Mil as of Mar. 2026. GuruFocus rates LABFF with a GF Score™ of 93/100 and a GF Value™ of $82.42. The stock has 1 warning sign investors should review.

Laboratorios Farmaceuticos Rovi's Ending Cash Position for the quarter that ended in Mar. 2026 was $112.6 Mil.

Laboratorios Farmaceuticos Rovi's quarterly Ending Cash Position increased from Sep. 2025 ($57.8 Mil) to Dec. 2025 ($114.7 Mil) but then declined from Dec. 2025 ($114.7 Mil) to Mar. 2026 ($112.6 Mil).

Laboratorios Farmaceuticos Rovi's annual Ending Cash Position increased from Dec. 2023 ($27.6 Mil) to Dec. 2024 ($28.5 Mil) and increased from Dec. 2024 ($28.5 Mil) to Dec. 2025 ($114.7 Mil).

Laboratorios Farmaceuticos Rovi Ending Cash Position Related Terms

Laboratorios Farmaceuticos Rovi Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Laboratorios Farmaceuticos Rovi's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Laboratorios Farmaceuticos Rovi Ending Cash Position Chart

Laboratorios Farmaceuticos Rovi Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 111.90 132.36 27.61 28.47 114.73

Laboratorios Farmaceuticos Rovi Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.68 53.19 57.81 114.73 112.59
LABFF
93GF Score
Laboratorios Farmaceuticos Rovi SA LABFF
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Laboratorios Farmaceuticos Rovi Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Laboratorios Farmaceuticos Rovi's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=31.834+82.892
=114.7

Laboratorios Farmaceuticos Rovi's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=113.267+-0.676
=112.6

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $112.6 Mil mean?
Laboratorios Farmaceuticos Rovi (LABFF) has a Ending Cash Position of $112.6 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Laboratorios Farmaceuticos Rovi and its competitors.
Is Laboratorios Farmaceuticos Rovi's Ending Cash Position too high?
Laboratorios Farmaceuticos Rovi's current Ending Cash Position is $112.6 Mil. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's Ending Cash Position compare to ZTS and UTHR?
Laboratorios Farmaceuticos Rovi's Ending Cash Position of $112.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. Laboratorios Farmaceuticos Rovi's current Ending Cash Position is $112.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (LABFF) has a current Ending Cash Position of $112.6 Mil. The stock's GF Value™ is $82.42, compared to a current price of $90.61 — trading 9.9% above its estimated fair value. The current Ending Cash Position is $112.6 Mil. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (LABFF), the current Ending Cash Position is $112.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Laboratorios Farmaceuticos Rovi (LABFF) Overvalued in 2026?

Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued. The current stock price of $90.61 is trading 9.9% above its estimated GF Value™ of $82.42.

Key valuation signals for LABFF:

  • Ending Cash Position: $112.6 Mil
  • GF Value™: $82.42 vs. price of $90.61 (9.9% above fair value)
  • GF Score™: 93/100 with 1 warning sign

No single metric tells the full story. See the LABFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Laboratorios Farmaceuticos Rovi Business Description

Address Julian Camarillo, 35, Madrid, ESP, 28037
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
93GF Score

Get the complete analysis for LABFF

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$90.61
Price
$82.42
GF Value